Margaret Kyle
Margaret Kyle
Bestätigte E-Mail-Adresse bei mines-paristech.fr
TitelZitiert vonJahr
Pharmaceutical price controls and entry strategies
MK Kyle
The Review of Economics and Statistics 89 (1), 88-99, 2007
2852007
Public & private spillovers, location and the productivity of pharmaceutical research
JL Furman, MK Kyle, IM Cockburn, R Henderson
National Bureau of Economic Research, 2006
1542006
Pharmaceutical Investments Before and After TRIPS
M Kyle
The Review of Economics and Statistics, 2011
147*2011
Generic competition and market exclusivity periods in pharmaceuticals
HG Grabowski, M Kyle
Managerial and Decision Economics 28 (4‐5), 491-502, 2007
1392007
Did US bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending?
AN Berger, MK Kyle, JM Scalise
Prudential Supervision: What Works and What Doesn't, 301-356, 2001
1252001
Surviving the gales of creative destruction: The determinants of product turnover
JM De Figueiredo, MK Kyle
Strategic Management Journal 27 (3), 241-264, 2006
117*2006
Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales*
DC Ling, ER Berndt, MK Kyle
Journal of Law and Economics 45 (S2), 691-723, 2002
1132002
The role of firm characteristics in pharmaceutical product launches
MK Kyle
The RAND Journal of Economics 37 (3), 602-618, 2006
1122006
The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches
ER Berndt, M Kyle, D Ling
Scanner Data and Price Indexes, 229-274, 2003
96*2003
Strategic responses to parallel trade
M Kyle
The BE Journal of Economic Analysis & Policy 11 (2), 2011
80*2011
Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets
B Waning, M Kyle, E Diedrichsen, L Soucy, J Hochstadt, T Bärnighausen, ...
Globalization and Health 6 (1), 9, 2010
652010
Markets for pharmaceutical products
FS Morton, M Kyle
Handbook of health economics 2, 763-823, 2011
602011
11. Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity
H Grabowski, M Kyle
The economics of corporate governance and mergers, 262, 2008
532008
Intellectual property protection and the geography of trade
M Delgado, M Kyle, AM McGahan
The Journal of Industrial Economics 61 (3), 733-762, 2013
51*2013
Competition and the efficiency of markets for technology
ML Allain, E Henry, M Kyle
Management Science 62 (4), 1000-1019, 2015
47*2015
Intellectual property rights and access to innovation: evidence from TRIPS
M Kyle, Y Qian
National Bureau of Economic Research, 2014
432014
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act
HG Grabowski, M Kyle, R Mortimer, G Long, N Kirson
Health Affairs 30 (11), 2157-2166, 2011
402011
Objective and self-report work performance measures: A comparative analysis
G Pransky, S Finkelstein, E Berndt, M Kyle, J Mackell, D Tortorice
International Journal of Productivity and Performance Management 55 (5), 390-399, 2006
372006
Would greater transparency and uniformity of health care prices benefit poor patients?
MK Kyle, DB Ridley
Health Affairs 26 (5), 1384-1391, 2007
352007
Does reimportation reduce price differences for prescription drugs? Lessons from the European Union
MK Kyle, JS Allsbrook, KA Schulman
Health services research 43 (4), 1308-1324, 2008
332008
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20